8-K
Stereotaxis, Inc. (STXS)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(D) of the Securities Exchange Act Of 1934
Date of report (Date of earliest event reported): May 10, 2022
STEREOTAXIS,
INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-36159 | 94-3120386 |
|---|---|
| (Commission<br> File Number) | (IRS<br> Employer Identification No.) |
| 710 North Tucker Boulevard, Suite 110, St. Louis, Missouri | 63101 |
| --- | --- |
| (Address<br> of Principal Executive Offices) | (Zip<br> Code) |
(314)678-6100
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securitiesregistered pursuant to Section 12(b) of the Act: [ ]
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.001 per share | STXS | NYSE<br> American LLC |
| Item 2.02 | Results of Operations and Financial Condition | |
| --- | --- |
On May 10, 2022, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2022 first quarter . A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Forward-Looking Statements and Additional Information
Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits |
|---|---|
| (d) | Exhibits. |
| --- | --- |
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated May 10, 2022. |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STEREOTAXIS, INC. | ||
|---|---|---|
| Date:<br> May 10, 2022 | By: | /s/ Kimberly R. Peery |
| Name: | Kimberly<br> R. Peery | |
| Title: | Chief<br> Financial Officer |
Exhibit 99.1
StereotaxisReports 2022 First Quarter Financial Results
ST.LOUIS, May 10, 2022 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022.
“Stereotaxis demonstrated continued progress on capital adoption despite a challenging macro environment,” said David Fischel, Chairman and CEO. “We are focused on improving our internal commercial capabilities while navigating the external challenges and aggressively advancing the innovations that structurally transform our commercial opportunity.”
“During the first quarter, we successfully launched new robotic practices with physicians entirely new to our technology in each of the United States, Europe, and China. We are delighted to see utilization at these practices, and across the installed base of Genesis systems, far above global averages. Since our last call we received an additional order for a Genesis system. We continue to expect multiple near-term orders and remain confident in our guidance of annual revenue growth driven by adoption of Genesis.”
“We are methodically advancing a robust innovation pipeline including a novel accessible robot, proprietary ablation catheters, vascular navigation devices, and operating room connectivity solution. Progress remains consistent with previously provided timelines and we look forward to the impact these innovations will have in 2023 and beyond. Collectively, these technologies serve as the foundational product ecosystem for a preeminent medical robotics company which can broadly transform endovascular interventions.”
2022First Quarter Financial Results
Revenue for the first quarter of 2022 totaled $7.0 million compared to $8.6 million in the prior year first quarter. This decrease was primarily due to lower system revenue in the current year. System revenue for the first quarter was $1.6 million and recurring revenue was $5.4 million, compared to $2.6 million and $5.8 million in the prior year first quarter.
Gross margin for the first quarter of 2022 was approximately 70%. Recurring revenue gross margin of 85% remains consistent with previous quarters and system gross margin of 21% continues to reflect significant allocation of overhead expenses over low manufacturing volumes. Operating expenses in the first quarter of $9.0 million include $2.5 million in non-cash stock compensation expense. Excluding non-cash stock compensation expense, adjusted operating expenses in the current quarter were $6.5 million, similar to adjusted operating expenses of $6.2 million in the prior year first quarter.
Operating loss and net loss for the first quarter of 2022 were both approximately ($4.1) million, compared to ($1.5) million for both in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($1.6) million, compared to ($0.1) million for both in the previous year. Negative free cash flow for the first quarter was ($3.3) million.
CashBalance and Liquidity
At March 31, 2022, Stereotaxis had cash and cash equivalents, including restricted cash, of $36.9 million and no debt.
ForwardLooking Expectations
Stereotaxis reiterates its expectation of revenue growth for the year driven by continued commercial adoption of the Genesis RMN system and stable recurring revenue. System revenue for the year will be primarily recognized in the second half of the year. Stereotaxis expects to modestly grow operating expenses with continued investment in key growth drivers, while maintaining a robust balance sheet that allows it to reach profitability without the need for additional financings. Stereotaxis is methodically establishing the product ecosystems that allow for significant future growth in electrophysiology and the broader field of endovascular surgery.
ConferenceCall and Webcast
Stereotaxis will host a conference call and webcast today, May 10, 2022, at 10:00 a.m. Eastern Time. To access the conference call, dial 1- 888-254-3590 (US and Canada) or 1-929-477-0448 (International) and give the participant pass code 5168103. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at https://ir.stereotaxis.com/.
AboutStereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
Thispress release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,“estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involverisks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differencesinclude, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’sproducts in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology,competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, theimpact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securitiesand Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statementsfor revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related toits purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies thatare outside of the Company’s control and may be revised, modified, delayed, or canceled.
CompanyContacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
STEREOTAXIS,INC.
STATEMENTSOF OPERATIONS
(Unaudited)
| (in thousands, except share and per share amounts) | Three Months Ended<br> March 31, | |||||
|---|---|---|---|---|---|---|
| 2022 | 2021 | |||||
| Revenue: | ||||||
| Systems | $ | 1,634 | $ | 2,602 | ||
| Disposables, service and accessories | 5,403 | 5,774 | ||||
| Sublease | - | 247 | ||||
| Total revenue | 7,037 | 8,623 | ||||
| Cost of revenue: | ||||||
| Systems | 1,292 | 1,435 | ||||
| Disposables, service and accessories | 821 | 925 | ||||
| Sublease | - | 247 | ||||
| Total cost of revenue | 2,113 | 2,607 | ||||
| Gross margin | 4,924 | 6,016 | ||||
| Operating expenses: | ||||||
| Research and development | 2,447 | 2,367 | ||||
| Sales and marketing | 2,946 | 2,947 | ||||
| General and administrative | 3,620 | 2,230 | ||||
| Total operating expenses | 9,013 | 7,544 | ||||
| Operating loss | (4,089 | ) | (1,528 | ) | ||
| Interest income (expense), net | 3 | (4 | ) | |||
| Net loss | $ | (4,086 | ) | $ | (1,532 | ) |
| Cumulative dividend on Series A convertible preferred stock | (331 | ) | (333 | ) | ||
| Net loss attributable to common stockholders | $ | (4,417 | ) | $ | (1,865 | ) |
| Net loss per share attributed to common stockholders: | ||||||
| Basic | $ | (0.06 | ) | $ | (0.02 | ) |
| Diluted | $ | (0.06 | ) | $ | (0.02 | ) |
| Weighted average number of common shares and equivalents: | ||||||
| Basic | 75,877,391 | 75,175,412 | ||||
| Diluted | 75,877,391 | 75,175,412 |
STEREOTAXIS,INC.
BALANCESHEETS
| (in thousands, except share amounts) | December 31, 2021 | ||||
|---|---|---|---|---|---|
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | 35,095 | $ | 38,739 | ||
| Restricted cash - current | 618 | 454 | |||
| Accounts receivable, net of allowance of 231 and 180 at 2022 and 2021, respectively | 4,693 | 5,406 | |||
| Inventories, net | 4,850 | 4,433 | |||
| Prepaid expenses and other current assets | 1,878 | 2,356 | |||
| Total current assets | 47,134 | 51,388 | |||
| Property and equipment, net | 3,260 | 2,632 | |||
| Restricted cash | 1,138 | 952 | |||
| Operating lease right-of-use assets | 5,644 | 5,735 | |||
| Prepaid and other non-current assets | 253 | 278 | |||
| Total assets | 57,429 | $ | 60,985 | ||
| Liabilities and stockholders’ equity | |||||
| Current liabilities: | |||||
| Accounts payable | 2,892 | $ | 4,189 | ||
| Accrued liabilities | 1,967 | 2,528 | |||
| Deferred revenue | 6,335 | 6,277 | |||
| Current portion of operating lease liabilities | 297 | 268 | |||
| Total current liabilities | 11,491 | 13,262 | |||
| Long-term deferred revenue | 2,076 | 2,238 | |||
| Operating lease liabilities | 5,754 | 5,842 | |||
| Other liabilities | 202 | 219 | |||
| Total liabilities | 19,523 | 21,561 | |||
| Series A - Convertible preferred stock: | |||||
| Convertible preferred stock, Series A, par value 0.001; 22,386 and 22,387 shares outstanding at 2022 and 2021, respectively | 5,584 | 5,584 | |||
| Stockholders’ equity: | |||||
| Convertible preferred stock, Series B, par value 0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022 and 2021 | 6 | 6 | |||
| Common stock, par value 0.001; 300,000,000 shares authorized, 74,647,329 and 74,618,240 shares issued at 2022 and 2021, respectively | 75 | 75 | |||
| Additional paid-in capital | 535,209 | 532,641 | |||
| Treasury stock, 4,015 shares at 2022 and 2021 | (206 | ) | (206 | ) | |
| Accumulated deficit | (502,762 | ) | (498,676 | ) | |
| Total stockholders’ equity | 32,322 | 33,840 | |||
| Total liabilities and stockholders’ equity | 57,429 | $ | 60,985 |
All values are in US Dollars.